The Microbiome and Tuberculosis: Early Evidence for Cross Talk

ABSTRACT Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sivaranjani Namasivayam, Alan Sher, Michael S. Glickman, Matthew F. Wipperman
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	antibiotics microbiome tuberculosis Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/110d8a1c2ded414aa4db9265da11293c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:110d8a1c2ded414aa4db9265da11293c
record_format	dspace
spelling	oai:doaj.org-article:110d8a1c2ded414aa4db9265da11293c2021-11-15T15:58:21ZThe Microbiome and Tuberculosis: Early Evidence for Cross Talk10.1128/mBio.01420-182150-7511https://doaj.org/article/110d8a1c2ded414aa4db9265da11293c2018-11-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01420-18https://doaj.org/toc/2150-7511ABSTRACT Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood. During the past two decades, it has become clear that the microbiota—the trillion organisms that reside at mucosal surfaces within and on the body—can exert a major influence on disease outcome through its effects on host innate and adaptive immune function and metabolism. This new recognition of the potentially pleiotropic participation of the microbiome in immune responses has raised the possibility that the microbiota may influence M. tuberculosis infection and/or disease. Similarly, treatment of TB may alter the healthy steady-state composition and function of the microbiome, possibly affecting treatment outcome in addition to other host physiological parameters. Herein, we review emerging evidence for how the microbiota may influence the transition points in the life cycle of TB infection, including (i) resistance to initial infection, (ii) initial infection to latent tuberculosis (LTBI), (iii) LTBI to reactivated disease, and (iv) treatment to cure. A major goal of this review is to frame questions to guide future scientific and clinical studies in this largely unexplored but increasingly important area of TB research.Sivaranjani NamasivayamAlan SherMichael S. GlickmanMatthew F. WippermanAmerican Society for MicrobiologyarticleantibioticsmicrobiometuberculosisMicrobiologyQR1-502ENmBio, Vol 9, Iss 5 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	antibiotics microbiome tuberculosis Microbiology QR1-502
spellingShingle	antibiotics microbiome tuberculosis Microbiology QR1-502 Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman The Microbiome and Tuberculosis: Early Evidence for Cross Talk
description	ABSTRACT Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood. During the past two decades, it has become clear that the microbiota—the trillion organisms that reside at mucosal surfaces within and on the body—can exert a major influence on disease outcome through its effects on host innate and adaptive immune function and metabolism. This new recognition of the potentially pleiotropic participation of the microbiome in immune responses has raised the possibility that the microbiota may influence M. tuberculosis infection and/or disease. Similarly, treatment of TB may alter the healthy steady-state composition and function of the microbiome, possibly affecting treatment outcome in addition to other host physiological parameters. Herein, we review emerging evidence for how the microbiota may influence the transition points in the life cycle of TB infection, including (i) resistance to initial infection, (ii) initial infection to latent tuberculosis (LTBI), (iii) LTBI to reactivated disease, and (iv) treatment to cure. A major goal of this review is to frame questions to guide future scientific and clinical studies in this largely unexplored but increasingly important area of TB research.
format	article
author	Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman
author_facet	Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman
author_sort	Sivaranjani Namasivayam
title	The Microbiome and Tuberculosis: Early Evidence for Cross Talk
title_short	The Microbiome and Tuberculosis: Early Evidence for Cross Talk
title_full	The Microbiome and Tuberculosis: Early Evidence for Cross Talk
title_fullStr	The Microbiome and Tuberculosis: Early Evidence for Cross Talk
title_full_unstemmed	The Microbiome and Tuberculosis: Early Evidence for Cross Talk
title_sort	microbiome and tuberculosis: early evidence for cross talk
publisher	American Society for Microbiology
publishDate	2018
url	https://doaj.org/article/110d8a1c2ded414aa4db9265da11293c
work_keys_str_mv	AT sivaranjaninamasivayam themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT alansher themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT michaelsglickman themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT matthewfwipperman themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT sivaranjaninamasivayam microbiomeandtuberculosisearlyevidenceforcrosstalk AT alansher microbiomeandtuberculosisearlyevidenceforcrosstalk AT michaelsglickman microbiomeandtuberculosisearlyevidenceforcrosstalk AT matthewfwipperman microbiomeandtuberculosisearlyevidenceforcrosstalk
_version_	1718427013176360960

The Microbiome and Tuberculosis: Early Evidence for Cross Talk

Ejemplares similares